{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:40:17Z","timestamp":1789609217288,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical (US)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s40120-015-0034-0","type":"journal-article","created":{"date-parts":[[2015,11,2]],"date-time":"2015-11-02T02:46:08Z","timestamp":1446432368000},"page":"105-124","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["The European LEMS Registry: Baseline Demographics and Treatment Approaches"],"prefix":"10.1007","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9810-5737","authenticated-orcid":false,"given":"Renato","family":"Mantegazza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joern P.","family":"Sieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwendal","family":"Le Masson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Desnuelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Essing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,2]]},"reference":[{"issue":"3","key":"34_CR1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.12998\/wjcc.v3.i3.293","volume":"3","author":"CE Bekircan-Kurt","year":"2015","unstructured":"Bekircan-Kurt CE, \u00c7ift\u00e7i ED, Kurne AT, Anlar B. Voltage gated calcium channel antibody-related neurological diseases. World J Clin Cases. 2015;3(3):293\u2013300.","journal-title":"World J Clin Cases"},{"issue":"2","key":"34_CR2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF03020488","volume":"49","author":"M Yamakage","year":"2002","unstructured":"Yamakage M, Namiki A. Calcium channels\u2014basic aspects of their structure, function and gene encoding; anesthetic action on the channels\u2014a review. Can J Anesth. 2002;49(2):151\u201364.","journal-title":"Can J Anesth"},{"key":"34_CR3","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJM199506013322203","volume":"332","author":"VA Lennon","year":"1995","unstructured":"Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert\u2013Eaton Syndrome and other paraneoplastic syndromes. N Engl J Med. 1995;332:1467\u201374.","journal-title":"N Engl J Med"},{"key":"34_CR4","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/pgmj.75.887.516","volume":"75","author":"U Seneviratne","year":"1999","unstructured":"Seneviratne U, de Silva R. Lambert\u2013Eaton myasthenic syndrome. Postgrad Med J. 1999;75:516\u201320.","journal-title":"Postgrad Med J"},{"issue":"2","key":"34_CR5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0035-3787(04)70888-7","volume":"160","author":"J Newsom-Davis","year":"2004","unstructured":"Newsom-Davis J. Lambert\u2013Eaton myasthenic syndrome. Rev Neurol (Paris). 2004;160(2):177\u201380.","journal-title":"Rev Neurol (Paris)."},{"key":"34_CR6","doi-asserted-by":"crossref","unstructured":"Titulaer M. Lambert\u2013Eaton myasthenic syndrome [Internet]. 2013 [updated 2013 November]. Available from: http:\/\/www.orpha.net .","DOI":"10.1093\/med\/9780199698073.003.0021"},{"issue":"6","key":"34_CR7","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s00415-003-1063-7","volume":"250","author":"PW Wirtz","year":"2003","unstructured":"Wirtz PW, Nijnuis MG, Sotodeh M, et al. The epidemiology of myasthenia gravis, Lambert\u2013Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland. J Neurol. 2003;250(6):698\u2013701.","journal-title":"J Neurol"},{"issue":"Pt.3","key":"34_CR8","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/brain\/111.3.577","volume":"111","author":"JH O\u2019Neill","year":"1988","unstructured":"O\u2019Neill JH, Murray NMF, Newsom-Davis J. The Lambert\u2013Eaton Myasthenic syndrome. A review of 50 cases. Brain. 1988;111(Pt.3):577\u201396.","journal-title":"Brain"},{"issue":"4","key":"34_CR9","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1212\/WNL.42.4.848","volume":"42","author":"L Gutmann","year":"1992","unstructured":"Gutmann L, Phillips LH, Gutmann L. Trends in the association of Lambert\u2013Eaton myasthenic syndrome with carcinoma. Neurology. 1992;42(4):848\u201350.","journal-title":"Neurology."},{"issue":"1","key":"34_CR10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/JTO.0b013e3181c3f4f1","volume":"5","author":"M Payne","year":"2010","unstructured":"Payne M, Bradbury P, Lang B, et al. Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer. J Thorac Oncol. 2010;5(1):34\u20138.","journal-title":"J Thorac Oncol."},{"key":"34_CR11","unstructured":"Stickler DE. Lambert\u2013Eaton Myasthenic Sydrome (LEMS) [Internet]. 2013 [updated 2013 May3]. Available from http:\/\/emedicine.medscape.com\/article\/1170810-overview ."},{"issue":"3","key":"34_CR12","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3111\/13696998.2012.660897","volume":"15","author":"L Harms","year":"2012","unstructured":"Harms L, Peter Sieb J-P, Williams AE, et al. Long-term disease history, clinical symptoms, health status, and healthcare utilization in patients suffering from Lambert Eaton myasthenic syndrome: results of a patient interview survey in Germany. J Med Econ. 2012;15(3):521\u201330.","journal-title":"J Med Econ."},{"key":"34_CR13","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1196\/annals.1254.065","volume":"998","author":"DB Sanders","year":"2003","unstructured":"Sanders DB. Lambert\u2013Eaton myasthenic syndrome: diagnosis and treatment. Ann N Y Acad Sci. 2003;998:500\u20138.","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"34_CR14","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1468-1331.2006.01266.x","volume":"13","author":"CA Vedeler","year":"2006","unstructured":"Vedeler CA, Antoine JC, Giometto B, et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol. 2006;13(7):682\u201390.","journal-title":"Eur J Neurol"},{"key":"34_CR15","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","volume":"17","author":"GO Skeie","year":"2010","unstructured":"Skeie GO, Apostolskib S, Evolic A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17:893\u2013902.","journal-title":"Eur J Neurol"},{"key":"34_CR16","volume-title":"European handbook of neurological management","author":"CA Vedeler","year":"2011","unstructured":"Vedeler CA, Antoine JC, Giometto B, et al. Paraneoplastic neurological syndromes. In: Gilhus NE, Barnes MP, Brainin M, editors. European handbook of neurological management, vol. 1. 2nd ed. Oxford (UK): Wiley-Blackwell; 2011.","edition":"2"},{"issue":"9","key":"34_CR17","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/mus.1140","volume":"24","author":"AAEM Quality Assurance Committee","year":"2001","unstructured":"AAEM Quality Assurance Committee. Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert\u2013Eaton myasthenic syndrome. Muscle Nerve. 2001;24(9):1239\u201347.","journal-title":"Muscle Nerve"},{"key":"34_CR18","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/mus.1139","volume":"24","author":"AAEM Quality Assurance Committee","year":"2001","unstructured":"AAEM Quality Assurance Committee. Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert\u2013Eaton myasthenic syndrome: summary statement. Muscle Nerve. 2001;24:1236\u20138.","journal-title":"Muscle Nerve"},{"key":"34_CR19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/clpt.2009.35","volume":"86","author":"PW Wirtz","year":"2009","unstructured":"Wirtz PW, Verschuren JJ, van Dijk JG, et al. Efficacy of 3,4 diaminopyridine and pyridostigmine in the treatment of Lambert\u2013Eaton myasthenic syndrome: a randomized double-blind placebo controlled cross over study. Clin Pharmacol Ther. 2009;86:44\u20138.","journal-title":"Clin Pharmacol Ther."},{"key":"34_CR20","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","volume":"841","author":"RJ Barohn","year":"1998","unstructured":"Barohn RJ, McIntire D, Herbelin L, et al. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci. 1998;841:769\u201372.","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"34_CR21","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/mus.880070311","volume":"7","author":"C Jablecki","year":"1984","unstructured":"Jablecki C. Lambert\u2013Eaton myasthenic syndrome. Muscle Nerve. 1984;7(3):250\u20137.","journal-title":"Muscle Nerve"},{"key":"34_CR22","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3109\/15563659509017992","volume":"33","author":"CE Boerma","year":"1995","unstructured":"Boerma CE, Rommes JH, van Leeuwen RB, Bakker J. Cardiac arrest following a iatrogenic by 3,4-diaminopyridine intoxication in a patient with Lambert\u2013Eaton myasthenic syndrome. J Toxicol Clin Toxicol. 1995;33:249\u201351.","journal-title":"J Toxicol Clin Toxicol"},{"key":"34_CR23","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-0404.1993.tb04205.x","volume":"88","author":"H Lundh","year":"1993","unstructured":"Lundh H, Nilsson O, Rosen I, Johansson S. Practical aspects of 3,4-diaminopyridine treatment of the Lambert\u2013Eaton myasthenic syndrome. Acta Neurol Scand. 1993;88:136\u201340.","journal-title":"Acta Neurol Scand"},{"key":"34_CR24","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1378\/chest.93.3.604","volume":"93","author":"PG Wilcox","year":"1988","unstructured":"Wilcox PG, Morrison NJ, Anzarut AR, Pardy RL. Lambert\u2013Eaton myasthenic syndrome involving the diaphragm. Chest. 1988;93:604\u20136.","journal-title":"Chest"},{"key":"34_CR25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1164\/ajrccm.159.1.9712108","volume":"159","author":"JL Hankinson","year":"1999","unstructured":"Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med. 1999;159:179\u201387.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"34_CR26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"The EuroQol Group","year":"1990","unstructured":"The EuroQol Group. EuroQol\u2014a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199\u2013208.","journal-title":"Health Policy"},{"key":"34_CR27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1136\/jnnp.58.1.85","volume":"58","author":"M Motomura","year":"1995","unstructured":"Motomura M, Johnston I, Lang B, Vincent A, Newsom-Davis J. An improved diagnostic assay for Lambert\u2013Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 1995;58:85\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"34_CR28","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/WNL.54.3.603","volume":"54","author":"DB Sanders","year":"2000","unstructured":"Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4-diaminopyridine in Lambert\u2013Eaton myasthenic syndrome. Neurology. 2000;54(3):603\u20137.","journal-title":"Neurology."},{"issue":"2","key":"34_CR29","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1055\/s-2004-830900","volume":"24","author":"M Mareska","year":"2004","unstructured":"Mareska M, Gutmann L. Lambert\u2013Eaton myasthenic syndrome. Semin Neurol. 2004;24(2):149\u201353.","journal-title":"Semin Neurol"},{"key":"34_CR30","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1212\/WNL.42.10.1944","volume":"42","author":"PD Clouston","year":"1992","unstructured":"Clouston PD, Saper CB, Arbizu T, et al. Paraneoplastic cerebellar degeneration. III. Cerebellar degeneration, cancer, and the Lambert\u2013Eaton myasthenic syndrome. Neurology. 1992;42:1944\u201350.","journal-title":"Neurology."},{"issue":"12","key":"34_CR31","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1136\/jnnp.2006.100594","volume":"77","author":"J Honnorat","year":"2006","unstructured":"Honnorat J. Understanding the physiopathology of paraneoplastic and genetic cerebellar ataxia. J Neurol Neurosurg Psychiatry. 2006;77(12):1299\u2013300.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"34_CR32","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1055\/s-2003-41135","volume":"23","author":"J Newsom-Davis","year":"2003","unstructured":"Newsom-Davis J. Therapy in myasthenia gravis and Lambert\u2013Eaton myasthenic syndrome. Semin Neurol. 2003;23(2):191\u20138.","journal-title":"Semin Neurol"},{"key":"34_CR33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2710.2011.01249.x","volume":"37","author":"DM Green","year":"2012","unstructured":"Green DM, Jones AC, Brain KR. Content variability of active drug substance in compounded oral 3,4-diaminopyridine products. J Clin Pharm Ther. 2012;37:53\u20137.","journal-title":"J Clin Pharm Ther"},{"key":"34_CR34","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1749-6632.1966.tb45484.x","volume":"135","author":"EH Lambert","year":"1966","unstructured":"Lambert EH. Defects of neuromuscular transmission in syndromes other than myasthenia gravis. Ann N Y Acad Sci. 1966;135:367\u201384.","journal-title":"Ann N Y Acad Sci"},{"issue":"23","key":"34_CR35","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJM198912073212303","volume":"321","author":"KM McEvoy","year":"1989","unstructured":"McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert\u2013Eaton myasthenic syndrome. N Engl J Med. 1989;321(23):1567\u201371.","journal-title":"N Engl J Med"},{"key":"34_CR36","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/jnnp.70.2.212","volume":"70","author":"P Maddison","year":"2001","unstructured":"Maddison P, Lang B, Mills K, Newsom-Davis J. Long term outcome in Lambert\u2013Eaton myasthenic syndrome without lung cancer. J Neurol Neurosurg Psychiatry. 2001;70:212\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"34_CR37","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1749-6632.1998.tb11023.x","volume":"841","author":"J Newsom-Davis","year":"1998","unstructured":"Newsom-Davis J. A treatment algorithm for Lambert\u2013Eaton myasthenic syndrome. Ann N Y Acad Sci. 1998;841:817\u201322.","journal-title":"Ann N Y Acad Sci"},{"key":"34_CR38","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1749-6632.2012.06769.x","volume":"1275","author":"P Maddison","year":"2012","unstructured":"Maddison P. Treatment of Lambert\u2013Eaton myasthenic syndrome. Ann N Y Acad. 2012;1275:78\u201384.","journal-title":"Ann N Y Acad."},{"key":"34_CR39","doi-asserted-by":"crossref","unstructured":"Gilhus NE. Lambert\u2013Eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy. Autoimmune Dis. 2011;2011:1\u20135. doi: 10.4061\/2011\/973808 .","DOI":"10.4061\/2011\/973808"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-015-0034-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T19:51:16Z","timestamp":1653421876000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40120-015-0034-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["34"],"URL":"https:\/\/doi.org\/10.1007\/s40120-015-0034-0","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,2]]}}}